Aerovate Therapeutics, Inc. (NASDAQ:AVTE - Get Free Report)'s stock price traded up 7.9% during mid-day trading on Friday . The company traded as high as $9.55 and last traded at $9.51. 171,880 shares changed hands during mid-day trading, an increase of 1,288% from the average session volume of 12,385 shares. The stock had previously closed at $8.81.
Aerovate Therapeutics Price Performance
The company has a market cap of $274.49 million, a price-to-earnings ratio of -3.17 and a beta of 0.95. The business's fifty day moving average price is $8.54 and its 200 day moving average price is $56.04.
Aerovate Therapeutics (NASDAQ:AVTE - Get Free Report) last announced its earnings results on Friday, April 25th. The company reported ($3.15) earnings per share for the quarter, topping analysts' consensus estimates of ($10.50) by $7.35. As a group, equities research analysts anticipate that Aerovate Therapeutics, Inc. will post -2.64 EPS for the current year.
Institutional Inflows and Outflows
Several hedge funds and other institutional investors have recently added to or reduced their stakes in AVTE. Two Sigma Advisers LP lifted its stake in Aerovate Therapeutics by 38.5% in the 4th quarter. Two Sigma Advisers LP now owns 153,600 shares of the company's stock worth $407,000 after purchasing an additional 42,700 shares in the last quarter. Northern Trust Corp lifted its stake in Aerovate Therapeutics by 6.3% in the 4th quarter. Northern Trust Corp now owns 106,692 shares of the company's stock worth $283,000 after purchasing an additional 6,296 shares in the last quarter. Renaissance Technologies LLC lifted its stake in Aerovate Therapeutics by 149.2% in the 4th quarter. Renaissance Technologies LLC now owns 44,600 shares of the company's stock worth $118,000 after purchasing an additional 26,700 shares in the last quarter. BNP Paribas Financial Markets purchased a new stake in Aerovate Therapeutics in the 4th quarter worth approximately $145,000. Finally, Rhumbline Advisers increased its holdings in shares of Aerovate Therapeutics by 67.3% in the 1st quarter. Rhumbline Advisers now owns 22,750 shares of the company's stock worth $57,000 after buying an additional 9,154 shares during the last quarter.
Aerovate Therapeutics Company Profile
(
Get Free Report)
Aerovate Therapeutics, Inc, a clinical-stage biopharmaceutical company, develops drugs that enhance the lives of patients with rare cardiopulmonary diseases in the United States. It focuses on advancing AV-101, a dry powder inhaled formulation of imatinib for the treatment of pulmonary arterial hypertension, which is in Phase 2b/Phase 3 trial.
Featured Stories
Before you consider Aerovate Therapeutics, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Aerovate Therapeutics wasn't on the list.
While Aerovate Therapeutics currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Looking for the next FAANG stock before everyone has heard about it? Enter your email address to see which stocks MarketBeat analysts think might become the next trillion dollar tech company.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
